AIMN Multicenter Study: Staging of Lymphomas Using PET/CT

Completed

• Conditions: Lymphoma

• Registration Number: NCT06179693
• Lead Sponsor: IRCCS San Raffaele

Brief Summary

In recent years, the introduction of PET/CT tomographs (which have now almost completely replaced tomographs equipped with PET alone), has allowed a significant increase in diagnostic accuracy in the majority of tumors. However, in order to reduce the radiation doses, administering CT images are acquired for patients at a low dose (generally 60mA 120kV) without the use of contrast agents. This prudential attitude, however, makes it essential to carry out "diagnostic" CT investigations which, at the end of the diagnostic process It leads to an increase in the dose administered for the patient rather than to savings.

This study aims to evaluate the possible advantages in diagnostic, economic and quality of life terms of PET/CT performed with diagnostic CT with intravenous contrast medium, with the aim of benefiting the neoplastic patient in the diagnostic process by optimizing (from a temporal and dosimetric point of view ) the diagnostic procedures to which it is subjected.

It is expected that the integrated PET/CT procedure can facilitate the process of staging the neoplasm and that this procedure can have a positive impact on the patient's quality of life while also reducing the costs incurred in terms of time and money.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10-07
• Primary Completion: 2011-02-24
• Study Completion: 2011-02-24
• Status Verified: 2023-12
• Study First Submitted: 2023-12-01
• Study First Submitted QC: 2023-12-11
• Last Update Submitted: 2023-12-11
• Study First Posted: 2023-12-22
• Last Update Posted: 2023-12-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Established lymphoma (non-Hodgkin's lymphoma and Hodgkin's disease) being staged;
• Performing the PET/CT examination within two weeks of diagnosis and before treatment;
• Signing of the Informed Consent.

Exclusion Criteria

• patients <18 years;
• Patients who have not signed the Informed Consent;
• Execution of previous anti-inflammatory or anti-inflammatory therapies in the 4 weeks preceding the PET exam.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PET/CT with contrast medium in a single session to diagnosis of patients with malignant limphoma.	2 years

Trial Locations

Locations (1)

Irccs San Raffaele; 🇮🇹 Milano, Italy